Halozyme Therapeutics Inc. HALO

NAS: HALO | ISIN: US40637H1095   8/12/2023
39,95 USD (-0,50%)
(-0,50%)   8/12/2023
Grafiek Halozyme Therapeutics Inc. Grafiek Halozyme Therapeutics Inc.

Halozyme Therapeutics Inc. in het nieuws

6 november 2023 · Halozyme Reports Third Quarter 2023 Financial And Operating Results · Persbericht

6 november 2023 · Halozyme and Acumen Pharmaceuticals Enter Global Collaboration and Non-Exclusive License Agreement for the ENHANZE® Technology in Alzheimer's Disease · Persbericht

30 oktober 2023 · Halozyme To Report Third Quarter 2023 Financial and Operating Results · Persbericht

19 oktober 2023 · Positive Topline Results Reported from Bristol Myers Squibb's Phase 3 CheckMate-67T Trial of Subcutaneous Nivolumab with Halozyme's ENHANZE® Drug Delivery Technology for Advanced or Metastatic Clear Cell Renal Cell Carcinoma · Persbericht

16 oktober 2023 · Update: Halozyme Announces Presentation of Positive Clinical Data of its High-Volume Auto-Injector Demonstrating Successful Rapid Subcutaneous Drug Delivery at 13th Annual PODD: Partnership Opportunities in Drug Delivery Conference · Persbericht

16 oktober 2023 · Halozyme Announces Positive Clinical Data of its High-Volume Auto-Injector Demonstrating Successful Rapid Subcutaneous Drug Delivery · Persbericht

31 augustus 2023 · Halozyme to Present at Upcoming Investor Conferences · Persbericht

29 augustus 2023 · Halozyme Announces Approval of Roche's Tecentriq® Subcutaneous (SC) with ENHANZE® in Great Britain · Persbericht

8 augustus 2023 · Halozyme Reports Second Quarter 2023 Financial And Operating Results · Persbericht

25 juli 2023 · Halozyme To Report Second Quarter 2023 Financial and Operating Results · Persbericht

Profiel Halozyme Therapeutics Inc.

Biotechnologie
Gezondheidstechnologie
Productie
Productie van biologische producten

Website: www.halozyme.com

Hoofdzetel: San Diego, California vlag Verenigde Staten

CEO: Helen Torley

Werknemers: 452

Aandelen Halozyme Therapeutics Inc.

Beurswaarde: 5,28 miljard USD

Effecten: 132,10 miljoen

Winst per aandeel (12 maand):  PLUS

Koers-winstverhouding:  PLUS

Beta: 0,72

Mijn selecties